Gene

PIK3R1

phosphoinositide-3-kinase regulatory subunit 1

Explore in graph →CI-GENE-00019757HGNC:8979 ENSG00000145675 NCBI 5295 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATM Mutation + CSF2RB Mutation + NTRK1 Mutation + PIK3CB Mutation + PIK3R1 Mutation + TP53 MutationATM TP53 PIK3R1 PIK3CB NTRK1 CSF2RB

Cohorts

Alteration frequency by cohort (151)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved151 cohort rows (showing 1, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Histiocytic and Dendritic Cell Neoplasms (MSK, 2025) hdcn_msk_2025	Histiocytic and Dendritic Cell Neoplasm	Ssm	1	1,270

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.
· N Engl J Med · 2025 · PMID 40961426 · validated civic_curation pubmed
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
· Oncogene · 2011 · PMID 21358673 · validated civic_curation pubmed

PIK3CA Mutation + PIK3R1 Mutation + PTEN MutationPIK3CA PTEN PIK3R11
Aspirin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID12602 In a randomized, double blind, placebo controlled adjuvant trial in colorectal carcinoma with PI3K pathway mutations (ALASCCA, NCT02647099; group B n = 312), aspirin 160 mg daily (group B n = 156) for… (full text at CIViC) PMID 40961426 · Martling et al., 2025 · Open in CIViC	civic

PIK3CA Mutation + PIK3R1 Mutation + PTEN MutationPIK3CA PTEN PIK3R11

Aspirin

Malignant Colorectal NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

accepted

EID12602

In a randomized, double blind, placebo controlled adjuvant trial in colorectal carcinoma with PI3K pathway mutations (ALASCCA, NCT02647099; group B n = 312), aspirin 160 mg daily (group B n = 156) for… (full text at CIViC)

PMID 40961426 · Martling et al., 2025 · Open in CIViC

civic

PIK3R1 Mutation2
Buparlisib	GlioblastomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID7073 In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC) PMID 30715997 · Wen et al., 2019 · Open in CIViC	civic
MTOR Kinase Inhibitor PP242	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1612 Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However,… (full text at CIViC) PMID 21358673 · Weigelt et al., 2011 · Open in CIViC	civic

PIK3R1 Mutation2

Buparlisib

GlioblastomaCURATED_BROADER

Predictive

Does Not Support Sensitivity Response

submitted

EID7073

In this multicenter, open-label, multi-arm, phase 2 trial, 65 patients with PI3K pathway aberrations (defined by PTEN and pAKT IHC-Status in 95%, genomic testing in 5%) were treated with the PI3K inhi… (full text at CIViC)

PMID 30715997 · Wen et al., 2019 · Open in CIViC

civic

MTOR Kinase Inhibitor PP242

Malignant Breast Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID1612

Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However,… (full text at CIViC)

PMID 21358673 · Weigelt et al., 2011 · Open in CIViC

civic